SILO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.420

Open

0.410

VWAP

0.41

Vol

381.62K

Mkt Cap

6.59M

Low

0.392

Amount

154.82K

EV/EBITDA(TTM)

--

Total Shares

16.27M

EV

-591.20K

EV/OCF(TTM)

--

P/S(TTM)

47.01

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Show More

Events Timeline

(ET)

2026-05-07

10:00:00

Silo Pharma Explores Ibogaine-Based Therapeutics for TBI

2026-04-22 (ET)

2026-04-22

17:10:00

Silo Pharma Expands into AI Technology Business

2026-04-06 (ET)

2026-04-06

16:20:00

Silo Pharma Receives Patent Grant Intent from European Patent Office

2026-02-23 (ET)

2026-02-23

16:40:00

Silo Pharma Authorizes Share Repurchase Program Up to $1M

2026-02-18 (ET)

2026-02-18

08:40:00

Silo Pharma Receives Patent Allowance for SPC-15 from Japan Patent Office

2025-12-30 (ET)

2025-12-30

08:40:00

Silo Pharma Enters LOI with Allucent for Clinical Research Services

2025-11-17 (ET)

2025-11-17

08:06:29

Silo Pharma collaborates with Allucent for upcoming FDA IND submission for SPC-15

News

Newsfilter

04-29Newsfilter

Federal Initiatives Propel Innovation in Mental Health Treatments

NASDAQ.COM

04-23NASDAQ.COM

Silo Pharma Expands into AI Technology Business

NASDAQ.COM

04-20NASDAQ.COM

Silo Pharma Advances Psychedelic Therapies for Mental Health

stocktwits

04-20stocktwits

Trump Signs Executive Order to Accelerate Psychedelic Research

Newsfilter

04-20Newsfilter

SPC-15 PTSD Program Aligns with Federal Push for Mental Health Therapies

stocktwits

04-07stocktwits

Silo Pharma Secures Patent for PTSD Therapy

Valuation Metrics

The current forward P/E ratio for Silo Pharma Inc (SILO.O) is 0.00, compared to its 5-year average forward P/E of -1.31. For a more detailed relative valuation and DCF analysis to assess Silo Pharma Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.31

Current PE

0.00

Overvalued PE

-0.13

Undervalued PE

-2.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

51.41

Current PS

0.00

Overvalued PS

92.91

Undervalued PS

9.91

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Outlook Therapeutics Inc

32.35M

Theriva Biologics Inc

11.80M

Cango Inc

198.55M

Silo Pharma Inc

8.38M

Blink Charging Co

99.60M

Cue Biopharma Inc

59.20M

cheapest top moving penny stocks

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Enveric Biosciences Inc

4.44M

Theriva Biologics Inc

11.80M

Clearmind Medicine Inc

2.00M

Cue Biopharma Inc

59.20M

Cango Inc

198.55M

TScan Therapeutics Inc

67.71M

what hasnt spiked up yet today

Intellectia · 1605 candidates

Price Change Pct: <= $1.00

Ticker

Name

Market Cap$

Captivision Inc

14.38M

WM Technology Inc

112.55M

Xiao-I Corp

26.23M

Ridgetech Inc

493.71K

Cemtrex Inc

13.00M

Cuprina Holdings (Cayman) Ltd

12.90M

biotech industry stock under 5 dollars

Intellectia · 282 candidates

Industry: Biotechnology & Medical ResearchPrice: <= $5.00

Ticker

Name

Market Cap$

Applied Therapeutics Inc

14.63M

Theriva Biologics Inc

6.85M

IO Biotech Inc

14.94M

Adial Pharmaceuticals Inc

6.04M

GRI Bio Inc

2.26M

Propanc Biopharma Inc

3.62M

Whales Holding SILO

Trading Trends

People Also Watch

Frequently Asked Questions

What is Silo Pharma Inc (SILO) stock price today?

The current price of SILO is 0.405 USD — it has decreased -3.57

What is Silo Pharma Inc (SILO)'s business?

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

What is the price predicton of SILO Stock?

Wall Street analysts forecast SILO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SILO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Silo Pharma Inc (SILO)'s revenue for the last quarter?

Silo Pharma Inc revenue for the last quarter amounts to 18.03K USD, decreased 0.00

What is Silo Pharma Inc (SILO)'s earnings per share (EPS) for the last quarter?

Silo Pharma Inc. EPS for the last quarter amounts to -0.07 USD, decreased -82.05

How many employees does Silo Pharma Inc (SILO). have?

Silo Pharma Inc (SILO) has 3 emplpoyees as of May 10 2026.

What is Silo Pharma Inc (SILO) market cap?

Today SILO has the market capitalization of 6.59M USD.